Clarient, Inc. Buys PVT Peer Applied Genomics, Inc. for $17.6 Million
12/22/2009 7:30:48 AM
More...
|
Clarient, Inc., BioView Initiate Alliance to Finalize Development and Commercialize Non-Invasive Molecular Diagnostic Test for Early Detection of Lung Cancer
12/14/2009 8:45:51 AM
More...
|
Clarient, Inc. Granted Exclusive License to Commercialize Cancer Biomarker by Minerva Biotechnologies Corporation Biomarker Identifying MUC1* Protein May Be Key to Treatment of Variety of Cancers
11/30/2009 11:44:15 AM
More...
|
Clarient, Inc. Reports 2009 Third Quarter; Nine Month Results Case Volumes Increase 22%; New Visibility from Historical Collections Impacts Current Period
11/4/2009 8:16:42 AM
More...
|
Clarient, Inc. to Present at William Blair Third Annual Emerging Growth Conference in New York City
9/29/2009 10:30:17 AM
More...
|
Safeguard Scientifics (SFE) Announces Sale of 2.4 Million Additional Clarient, Inc. Shares Pursuant to Overallotment Option
9/22/2009 8:49:31 AM
More...
|
Clarient, Inc. Reports Second Quarter Revenue Up 40 Percent
8/5/2009 8:24:38 AM
More...
|
Health Discovery Corporation (DWCM.OB) Announces Publication of Peer Reviewed Scientific Paper Demonstrating the Clinical Validity of the Four-Gene Prostate Cancer Test Licensed to Abbott GmbH, Quest Diagnostics Inc. (DGX) and Clarient, Inc.
7/14/2009 8:35:38 AM
More...
|
Clarient, Inc. Launches New Gene Mutation Test to Help Select Therapy for Non-Small Cell Lung Cancer
6/17/2009 8:49:48 AM
More...
|
Safeguard Scientifics (SFE)' Portfolio Company, Clarient, Inc. Completes Second Tranche of Private Placement of Up to $50 millionwith Oak Investment Partners
5/18/2009 7:15:10 AM
More...
|
|